How much funding did Hemogenyx (HOPHF) raise related to the 2025 results?

Hemogenyx raised £2.7m before expenses via allotment and issue of new ordinary shares in 2025. According to the company, an additional £5.5m was raised in early 2026.

Hemogenyx Pharmaceuticals PLC Announces Final Results

Q: What did Hemogenyx (HOPHF) announce about the HG-CT-1 clinical program on April 30, 2026?

Hemogenyx announced the Phase 1 trial of HG-CT-1 commenced and the DSMB authorised dose-expansion. According to the company, a paediatric arm was also opened and further trial details are in the Annual Report.

Q: What does opening a paediatric arm mean for Hemogenyx's HG-CT-1 trial?

Opening a paediatric arm means the trial will enrol paediatric patients to assess HG-CT-1 in younger populations. According to the company, this expands the study's scope and safety data collection across age groups.

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Hemogenyx Pharmaceuticals (HOPHF) published final audited results for year ended 31 December 2025 and posted the Annual Report online. Key developments: commencement of the Phase 1 trial of HG-CT-1, DSMB clearance to enter dose-expansion, opening of a paediatric arm, and equity raises of £2.7m (2025) and £5.5m (early 2026).

The company signposted the full final results and related documents are available on its website and via the regulatory PDF link.

Positive

Phase 1 start for HG-CT-1 CAR-T therapy
Independent DSMB authorised progression to dose-expansion
Opened a paediatric arm of the Phase 1 trial
Raised £2.7m via share issue in 2025 and £5.5m in early 2026

Negative

HG-CT-1 remains in early-stage Phase 1 development, with clinical and commercial risks
Company issued new ordinary shares, which may dilute existing shareholders

04/30/2026 - 12:25 PM

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

LONDON, UK / ACCESS Newswire / April 30, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2025. The Annual Report is available to view on the Company's website at https://hemogenyx.com/.

Key Highlights

The Company commenced the Phase 1 clinical trial of HG-CT-1, its lead CAR-T cell therapy candidate.
The independent Data Safety Monitoring Board authorised the Phase 1 trial of HG-CT-1 to progress into the dose-expansion phase.
The Company opened a paediatric arm of the Phase 1 clinical trial of HG-CT-1.
The Company successfully raised £2.7 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2025, with a further £5.5 million raised in early 2026.

Further details of these developments are set out in the full text of the final results for the year ended 31 December 2025 below.

Please refer to the attached PDF document to view the full announcement.

http://www.rns-pdf.londonstockexchange.com/rns/6603C_1-2026-4-30.pdf

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl

AlbR Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

FAQ

What did Hemogenyx (HOPHF) announce about the HG-CT-1 clinical program on April 30, 2026?

Hemogenyx announced the Phase 1 trial of HG-CT-1 commenced and the DSMB authorised dose-expansion. According to the company, a paediatric arm was also opened and further trial details are in the Annual Report.

Has the DSMB approved progression of Hemogenyx's HG-CT-1 trial?

Yes. The independent Data Safety Monitoring Board authorised entry into the dose-expansion phase. According to the company, this authorisation follows initial safety reviews during the trial's dose-escalation stages.

What does opening a paediatric arm mean for Hemogenyx's HG-CT-1 trial?

Opening a paediatric arm means the trial will enrol paediatric patients to assess HG-CT-1 in younger populations. According to the company, this expands the study's scope and safety data collection across age groups.

Where can investors find Hemogenyx's full audited results for the year ended 31 December 2025?

Investors can view the Annual Report and final audited results on Hemogenyx's official website and the regulatory PDF link provided in the announcement. According to the company, the report is available online for download.